Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

Also called NCT05350969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 294 participants (enrolled count) (from the registry)
Sponsor
Cardior Pharmaceuticals GmbH (from the registry)
Registry
  • NCT NCT05350969
  • EU CT 2023-507569-24-00
  • EudraCT 2021-006040-27
Other papers using this trial's data
  • The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial Nature medicine, 2026-07 DOI, PubMed 42108271, PMC13375544 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Czechia, Germany, Greece, Hungary, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05350969. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-11 (actual); primary completion 2024-09-26 (actual). Results posted on 2026-08-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
Acronym
HF-REVERT
Condition
Myocardial Infarction, Acute
Condition
Heart Failure, Left Sided
Intervention (Drug)
CDR132L
Intervention (Drug)
Placebo to CDR132L
Lead sponsor
Cardior Pharmaceuticals GmbH (class: industry)

Record details

Record id
cardio:ct-nct05350969
Content hash
87e11027f3510424e198be302519256265be376dbce4b55b27ddb082a94fdf4c